Page 50 - Merck Sharp News Today

The flimsy decision in In re Acetaminophen − ASH-ADHD Products Liability Litigation, 2022 WL 17348351 (S.D.N.Y. Nov. 14, 2022), leaves us scratching…

Could one of your patients benefit from the latest clinical trials enrolling patients with leukemia or lymphoma?

BASEL, Switzerland, Jan. 5, 2023 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced that it has entered

/PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the...

First-line pembrolizumab-axitinib leads to lower health care resource utilization than ipilimumab-nivolumab in metastatic renal cell carcinoma.

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer BASEL, Switzerland – 5th January 2023 - Nouscom, a clinical stage immuno-oncology...

In April 2021, Kulun Biotech secured over $77m in a funding round led by CMC-SDIC Capital.

The prevalence of pancreatic cancer has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cancer, the robust pipeline

Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups, according to results...

PFS2 is significantly longer with lenvatinib-pembrolizumab than with sunitinib in patients with advanced renal cell carcinoma.